Catalyst Biosciences (NASDAQ:CBIO) Shares Cross Above 200 Day Moving Average of $0.26

Posted by on Aug 8th, 2023

Catalyst Biosciences, Inc. (NASDAQ:CBIO – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.26 and traded as high as $0.37. Catalyst Biosciences shares last traded at $0.35, with a volume of 145,309 shares trading hands.

Catalyst Biosciences Trading Up 5.5 %

The company has a market cap of $13.22 million, a PE ratio of 1.67 and a beta of 1.10. The stock has a 50 day moving average price of $0.32 and a 200 day moving average price of $0.26.

Catalyst Biosciences (NASDAQ:CBIO – Get Free Report) last released its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter. Equities analysts expect that Catalyst Biosciences, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. purchased a new position in Catalyst Biosciences during the second quarter valued at $36,000. Bank of New York Mellon Corp increased its holdings in shares of Catalyst Biosciences by 187.9% in the 1st quarter. Bank of New York Mellon Corp now owns 216,807 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 141,498 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Catalyst Biosciences in the 1st quarter worth $52,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Catalyst Biosciences by 38.2% in the 3rd quarter. Renaissance Technologies LLC now owns 1,101,270 shares of the biopharmaceutical company’s stock worth $555,000 after purchasing an additional 304,284 shares in the last quarter. Hedge funds and other institutional investors own 8.93% of the company’s stock.

Catalyst Biosciences Company Profile

(Get Free Report)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease.

Featured Stories

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.